SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- DAIICHI, a leading car seat company in Korea, has launched the portable car seat 'Easy Carry 2' and portable stroller 'The Space' in Indonesia, optimized for travel and meet safety and convenience.
DAIICHI is the No. 1 car seat manufacturer in Korea with a 50% market share. Founded in 2001, DAIICHI is a car seat company that is loved by customers for its made in Korea car seats called the 'national car seat' in Korea.
In addition, DAIICHI is a baby products company solidifying its position in the global market by selling car seats in more than 100 offline stores in Korea and exporting to 12 countries including Japan, Thailand, Indonesia, Singapore, and Romania.
DAIICHI has been the main sponsor for numerous TV dramas, movies, and entertainment programs, and in particular, DAIICHI supported the production of the drama <Spring Night>, which was recently loved by Netflix, starring Jung Hae-in, and also promoted DAIICHI products through entertainment programs such as <Dad, Where Are We Going> and <The Return of Superman>.
A DAIICHI representative stated, "Indonesia is one of the countries with the most islands in the world, and since travel is a part of daily life, there are many families traveling with children. DAIICHI developed these products to provide safe and convenient travel for these families, and we expect that these products, which have applied Korea's high quality standards, will be loved by Indonesian parents."
Portable strollers optimized for Indonesia
The portable stroller 'The Space' is an ultra-lightweight design that can be carried on board, so there is no need to check the stroller in as luggage when traveling, and it is easy for parents to carry it, and it is an automatic folding stroller that automatically folds with the click of a button with one hand.
Also, since it is a portable stroller with perfect handling, folding, and even a basket car seat combination, it is expected to be very popular in Indonesia, where people travel and move frequently.
DAIICHI's portable car seat 'Easy Carry 2' and 'The Space' portable stroller can be found at the DAIICHI Premium booth located at the IMBEX exhibition hall (Jakarta convention center) from November 29 to December 1, 2024, and can also be seen at Plaza Senayen mall.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
DAIICHI, the No. 1 car seat brand in Korea, officially launches portable car seats and strollers in Indonesia
DAIICHI, the No. 1 car seat brand in Korea, officially launches portable car seats and strollers in Indonesia
DAIICHI, the No. 1 car seat brand in Korea, officially launches portable car seats and strollers in Indonesia
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
